SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (264)9/12/2002 9:08:03 PM
From: scaram(o)uche  Read Replies (2) of 631
 
>> on Track <<

I'd be ticked if I were a BGEN shareholder. The response could -- theoretically -- be that amevive should go before an advisory committee again.

Putting all of the BS aside..... this is a resubmission, addressing major deficiencies. Moreover, the response OBJECTIVE is within six months, but FDA is not obligated to meet it.

There you go, Adam!! Begin writing. Be sure to source the same interpretation, elsewhere. Here's an exclusive for you..... MEDI followed BGEN into the same goop. Read the BTRN thread for the last three years to see how these agents should have been used, and then go find your own expert to report the same spin on spin.

I am not implying that amevive is not safe. And it's obviously effective, highly efficacious, for some patients. But, IMO, there's been little in the way of biological insight behind the clinical testing.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News